CAGE Bio Announces Phase 2b Trial for CGB-500 (1% Tofacitinib), a Breakthrough Topical JAK Inhibitor for Moderate to Severe Atopic Dermatitis
SCS
0.0200
The Fort Worth Press - CAGE Bio Announces Phase 2b Trial for CGB-500 (1% Tofacitinib), a Breakthrough Topical JAK Inhibitor for Moderate to Severe Atopic Dermatitis
USD
-
AED 3.672499
AFN 66.265317
ALL 82.40468
AMD 381.537936
ANG 1.790403
AOA 917.000395
ARS 1449.250041
AUD 1.512185
AWG 1.8025
AZN 1.701917
BAM 1.670125
BBD 2.014261
BDT 122.309039
BGN 1.670125
BHD 0.377012
BIF 2957.004398
BMD 1
BND 1.292857
BOB 6.910892
BRL 5.541298
BSD 1.000043
BTN 89.607617
BWP 14.066863
BYN 2.939243
BYR 19600
BZD 2.011357
CAD 1.379195
CDF 2558.501249
CHF 0.795195
CLF 0.023213
CLP 910.640111
CNY 7.04095
CNH 7.03416
COP 3860.210922
CRC 499.466291
CUC 1
CUP 26.5
CVE 94.159088
CZK 20.77025
DJF 178.088041
DKK 6.376535
DOP 62.644635
DZD 130.069596
EGP 47.690961
ERN 15
ETB 155.362794
EUR 0.853703
FJD 2.283697
FKP 0.747408
GBP 0.74712
GEL 2.685003
GGP 0.747408
GHS 11.486273
GIP 0.747408
GMD 72.999948
GNF 8741.72751
GTQ 7.663208
GYD 209.231032
HKD 7.781017
HNL 26.346441
HRK 6.432802
HTG 131.121643
HUF 330.045497
IDR 16697
ILS 3.20705
IMP 0.747408
INR 89.577497
IQD 1310.106315
IRR 42099.999884
ISK 125.629729
JEP 0.747408
JMD 160.018787
JOD 0.709015
JPY 157.5835
KES 128.909953
KGS 87.450384
KHR 4013.492165
KMF 419.999986
KPW 899.999767
KRW 1475.719978
KWD 0.30723
KYD 0.83344
KZT 517.535545
LAK 21660.048674
LBP 89556.722599
LKR 309.636651
LRD 177.012083
LSL 16.776824
LTL 2.95274
LVL 0.60489
LYD 5.420776
MAD 9.166901
MDL 16.930959
MGA 4548.055164
MKD 52.559669
MMK 2100.286841
MNT 3551.115855
MOP 8.015542
MRU 40.023056
MUR 46.149683
MVR 15.449418
MWK 1734.170189
MXN 18.022785
MYR 4.077022
MZN 63.894334
NAD 16.776824
NGN 1460.159533
NIO 36.804577
NOK 10.13072
NPR 143.372187
NZD 1.736935
OMR 0.385423
PAB 1.000043
PEN 3.367832
PGK 4.254302
PHP 58.570975
PKR 280.195978
PLN 3.590096
PYG 6709.363392
QAR 3.645959
RON 4.335397
RSD 100.234832
RUB 80.459966
RWF 1456.129115
SAR 3.750995
SBD 8.146749
SCR 15.161607
SDG 601.498945
SEK 9.267885
SGD 1.292865
SHP 0.750259
SLE 24.04961
SLL 20969.503664
SOS 570.513642
SRD 38.441497
STD 20697.981008
STN 20.921395
SVC 8.750267
SYP 11058.461434
SZL 16.774689
THB 31.425042
TJS 9.215661
TMT 3.5
TND 2.927287
TOP 2.40776
TRY 42.814755
TTD 6.787925
TWD 31.518899
TZS 2495.196618
UAH 42.285385
UGX 3577.131634
UYU 39.263908
UZS 12022.543871
VES 282.15965
VND 26312.5
VUV 121.02974
WST 2.787828
XAF 560.144315
XAG 0.014815
XAU 0.000229
XCD 2.70255
XCG 1.8024
XDR 0.69664
XOF 560.144315
XPF 101.840229
YER 238.398055
ZAR 16.765585
ZMK 9001.200765
ZMW 22.626703
ZWL 321.999592
- Jailed Malaysian ex-PM Najib loses bid for house arrest
- Banned film exposes Hong Kong's censorship trend, director says
- Duffy, Patel force West Indies collapse as NZ close in on Test series win
- Australian state pushes tough gun laws, 'terror symbols' ban after shooting
- A night out on the town during Nigeria's 'Detty December'
- US in 'pursuit' of third oil tanker in Caribbean: official
- CO2 soon to be buried under North Sea oil platform
- Steelers edge Lions as Bears, 49ers reach playoffs
- India's Bollywood counts costs as star fees squeeze profits
- McCullum admits errors in Ashes preparations as England look to salvage pride
CAGE Bio Announces Phase 2b Trial for CGB-500 (1% Tofacitinib), a Breakthrough Topical JAK Inhibitor for Moderate to Severe Atopic Dermatitis
CAGE Bio, Inc., a clinical-stage biotechnology company advancing innovative therapies for high incidence immuno-dermatological disorders, today announced the initiation of a Phase 2b dose-ranging trial for its CGB-500 product. This topical JAK inhibitor ointment, developed using CAGE Bio's proprietary ionic liquid technology, represents a potential breakthrough for low body surface area (BSA), moderate to severe atopic dermatitis (AD) condition.
CGB-500 delivers medicine directly through the skin, combining high efficacy with minimal systemic exposure. Results from the 2024 Phase 2a trial showed efficacy comparable to biologics, outperforming current best-in-class topical treatments while maintaining a significantly lower side-effect profile. Specifically, CGB-500 had an 8-week treatment success of 95% (IGA score of "0" or "1" and > 2 grade improvement ).
This larger Phase 2b trial (n=180) will focus on optimizing dosing regimens and further assessing the safety and efficacy of CGB-500. This pivotal step underscores CAGE Bio's commitment to addressing the unmet needs of patients with moderate to severe AD and low body surface area (BSA) involvement, where treatment speed and efficacy must be balanced with the cost of systemic exposure and side effects.
"CGB-500 offers a promising solution for patients seeking rapid and effective localized relief potentially avoiding systemic therapies and their associated side-effects" said Dr. Justin Ko MD, a board-certified dermatologist in San Francisco Bay Area.
"Our ionic liquid platform continues to demonstrate its potential in enabling highly effective and targeted topical therapies. With the Phase 2b trial now underway, we are one step closer to transforming how atopic dermatitis is treated," said Nitin Joshi, Ph.D., CEO of CAGE Bio.
Atopic dermatitis is a chronic inflammatory skin condition affecting millions globally. Patients with highly localized, moderate to severe symptoms face limited treatment options. CGB-500 seeks to fill this gap, offering a high efficacy alternative with dramatically lower systemic exposure.
CAGE Bio remains committed to advancing clinical programs that deliver transformative therapies (efficacy of a biologic with safety of a topical ) for immuno-dermatological disorders.
About CAGE Bio
CAGE Bio is a clinical-stage biotechnology company developing innovative localized therapies for immune-mediated dermatological conditions. Its proprietary ionic liquid technology ensures effective drug delivery to target areas with minimal systemic exposure, improving patient outcomes.
Phone: +1 (650) 996-1845
email. [email protected]
SOURCE: CAGE Bio Inc.
D.Ford--TFWP
